1. Home
  2. BSL vs MDWD Comparison

BSL vs MDWD Comparison

Compare BSL & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$13.62

Market Cap

177.9M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.82

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
MDWD
Founded
2010
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.9M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BSL
MDWD
Price
$13.62
$18.82
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
71.9K
93.0K
Earning Date
01-01-0001
11-20-2025
Dividend Yield
9.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.15
52 Week Low
$12.19
$14.14
52 Week High
$14.56
$22.51

Technical Indicators

Market Signals
Indicator
BSL
MDWD
Relative Strength Index (RSI) 41.64 55.76
Support Level $13.50 $18.55
Resistance Level $13.71 $19.05
Average True Range (ATR) 0.06 0.57
MACD 0.01 0.06
Stochastic Oscillator 57.14 66.25

Price Performance

Historical Comparison
BSL
MDWD

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: